Swatek KN, Komander D. Ubiquitin modifications. Cell Res. 2016;26(4):399–422.
Pickart CM. Mechanisms underlying ubiquitination. Annu Rev Biochem. 2001;70:503–33.
Hershko A, Ciechanover A. The ubiquitin system. Annu Rev Biochem. 1998;67:425–79.
Dikic I, Schulman BA. An expanded lexicon for the ubiquitin code. Nat Rev Mol Cell Biol. 2023;24(4):273–87.
Chen ZJ, Sun LJ. Nonproteolytic functions of ubiquitin in cell signaling. Mol Cell. 2009;33(3):275–86.
Kulathu Y, Komander D. Atypical ubiquitylation – the unexplored world of Polyubiquitin beyond Lys48 and Lys63 linkages. Nat Rev Mol Cell Biol. 2012;13(8):508–23.
Yuan WC, Lee YR, Lin SY, Chang LY, Tan YP, Hung CC, et al. K33-Linked polyubiquitination of Coronin 7 by Cul3-KLHL20 ubiquitin E3 ligase regulates protein trafficking. Mol Cell. 2014;54(4):586–600.
Ulrich HD, Walden H. Ubiquitin signalling in DNA replication and repair. Nat Rev Mol Cell Biol. 2010;11(7):479–89.
Liu F, Chen J, Li K, Li H, Zhu Y, Zhai Y, et al. Ubiquitination and deubiquitination in cancer: from mechanisms to novel therapeutic approaches. Mol Cancer. 2024;23(1):148.
Morreale FE, Walden H. Types of ubiquitin ligases. Cell. 2016;165(1):248–e1.
Petroski MD, Deshaies RJ. Function and regulation of cullin-RING ubiquitin ligases. Nat Rev Mol Cell Biol. 2005;6(1):9–20.
Skaar JR, Florens L, Tsutsumi T, Arai T, Tron A, Swanson SK, et al. PARC and CUL7 form atypical Cullin RING ligase complexes. Cancer Res. 2007;67(5):2006–14.
Baek K, Scott DC, Henneberg LT, King MT, Mann M, Schulman BA. Systemwide disassembly and assembly of SCF ubiquitin ligase complexes. Cell. 2023;186(9):1895–911. e21.
Reitsma JM, Liu X, Reichermeier KM, Moradian A, Sweredoski MJ, Hess S, et al. Composition and regulation of the cellular repertoire of SCF ubiquitin ligases. Cell. 2017;171(6):1326–e3914.
Jin J, Cardozo T, Lovering RC, Elledge SJ, Pagano M, Harper JW. Systematic analysis and nomenclature of mammalian F-box proteins. Genes Dev. 2004;18(21):2573–80.
Liu Y, Jurczak MJ, Lear TB, Lin B, Larsen MB, Kennerdell JR, et al. A Fbxo48 inhibitor prevents pAMPKalpha degradation and ameliorates insulin resistance. Nat Chem Biol. 2021;17(3):298–306.
Simon-Kayser B, Scoul C, Renaudin K, Jezequel P, Bouchot O, Rigaud J, et al. Molecular cloning and characterization of FBXO47, a novel gene containing an F-box domain, located in the 17q12 band deleted in papillary renal cell carcinoma. Genes Chromosomes Cancer. 2005;43(1):83–94.
Hu J, Zacharek S, He YJ, Lee H, Shumway S, Duronio RJ, et al. WD40 protein FBW5 promotes ubiquitination of tumor suppressor TSC2 by DDB1-CUL4-ROC1 ligase. Genes Dev. 2008;22(7):866–71.
Hopf LVM, Baek K, Klugel M, von Gronau S, Xiong Y, Schulman BA. Structure of CRL7(FBXW8) reveals coupling with CUL1-RBX1/ROC1 for multi-cullin-RING E3-catalyzed ubiquitin ligation. Nat Struct Mol Biol. 2022;29(9):854–62.
Zheng N, Shabek N. Ubiquitin ligases: Structure, Function, and regulation. Annu Rev Biochem. 2017;86:129–57.
Frescas D, Pagano M. Deregulated proteolysis by the F-box proteins SKP2 and beta-TrCP: tipping the scales of cancer. Nat Rev Cancer. 2008;8(6):438–49.
Orlicky S, Tang X, Willems A, Tyers M, Sicheri F. Structural basis for phosphodependent substrate selection and orientation by the SCFCdc4 ubiquitin ligase. Cell. 2003;112(2):243–56.
Abbas T, Mueller AC, Shibata E, Keaton M, Rossi M, Dutta A. CRL1-FBXO11 promotes Cdt2 ubiquitylation and degradation and regulates Pr-Set7/Set8-mediated cellular migration. Mol Cell. 2013;49(6):1147–58.
Kuchay S, Duan S, Schenkein E, Peschiaroli A, Saraf A, Florens L, et al. FBXL2- and PTPL1-mediated degradation of p110-free p85beta regulatory subunit controls the PI(3)K signalling cascade. Nat Cell Biol. 2013;15(5):472–80.
Skaar JR, Pagan JK, Pagano M. Mechanisms and function of substrate recruitment by F-box proteins. Nat Rev Mol Cell Biol. 2013;14(6):369–81.
Yoshida Y, Chiba T, Tokunaga F, Kawasaki H, Iwai K, Suzuki T, et al. E3 ubiquitin ligase that recognizes sugar chains. Nature. 2002;418(6896):438–42.
Yoshida Y, Tokunaga F, Chiba T, Iwai K, Tanaka K, Tai T. Fbs2 is a new member of the E3 ubiquitin ligase family that recognizes sugar chains. J Biol Chem. 2003;278(44):43877–84.
D’Angiolella V, Donato V, Forrester FM, Jeong YT, Pellacani C, Kudo Y, et al. Cyclin F-mediated degradation of ribonucleotide reductase M2 controls genome integrity and DNA repair. Cell. 2012;149(5):1023–34.
D’Angiolella V, Donato V, Vijayakumar S, Saraf A, Florens L, Washburn MP, et al. SCF(Cyclin F) controls centrosome homeostasis and mitotic fidelity through CP110 degradation. Nature. 2010;466(7302):138–42.
Cao S, Garcia SF, Shi H, James EI, Kito Y, Shi H, et al. Recognition of BACH1 quaternary structure degrons by two F-box proteins under oxidative stress. Cell. 2024;187(26):7568–e8422.
Hanahan D, Weinberg RA. The hallmarks of cancer. Cell. 2000;100(1):57–70.
Randle SJ, Laman H. F-box protein interactions with the hallmark pathways in cancer. Semin Cancer Biol. 2016;36:3–17.
Wang Z, Liu P, Inuzuka H, Wei W. Roles of F-box proteins in cancer. Nat Rev Cancer. 2014;14(4):233–47.
Xu J, Zhou W, Yang F, Chen G, Li H, Zhao Y, et al. The beta-TrCP-FBXW2-SKP2 axis regulates lung cancer cell growth with FBXW2 acting as a tumour suppressor. Nat Commun. 2017;8:14002.
Islam S, Dutta P, Sahay O, Gopalakrishnan K, Muhury SR, Parameshwar P, et al. Feedback-regulated transcriptional repression of FBXO31 by c-Myc triggers ovarian cancer tumorigenesis. Int J Cancer. 2022;150(9):1512–24.
Hanahan D. Hallmarks of cancer: new dimensions. Cancer Discov. 2022;12(1):31–46.
Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell. 2011;144(5):646–74.
Perez-Gonzalez A, Bevant K, Blanpain C. Cancer cell plasticity during tumor progression, metastasis and response to therapy. Nat Cancer. 2023;4(8):1063–82.
Nieto MA, Huang RY, Jackson RA, Thiery JP. Emt: 2016 Cell. 2016;166(1):21–45.
Le Magnen C, Shen MM, Abate-Shen C. Lineage plasticity in cancer progression and treatment. Annu Rev Cancer Biol. 2018;2:271–89.
Sun R, Xie HY, Qian JX, Huang YN, Yang F, Zhang FL, et al. FBXO22 possesses both protumorigenic and antimetastatic roles in breast cancer progression. Cancer Res. 2018;78(18):5274–86.
Zou S, Ma C, Yang F, Xu X, Jia J, Liu Z. FBXO31 suppresses gastric cancer EMT by targeting Snail1 for proteasomal degradation. Mol Cancer Res. 2018;16(2):286–95.
Ryu KJ, Park SM, Park SH, Kim IK, Han H, Kim HJ, et al. p38 stabilizes snail by suppressing DYRK2-Mediated phosphorylation that is required for GSK3beta-betaTrCP-Induced snail degradation. Cancer Res. 2019;79(16):4135–48.
Zhang Y, Zhang X, Ye M, Jing P, Xiong J, Han Z, et al. FBW7 loss promotes epithelial-to-mesenchymal transition in non-small cell lung cancer through the stabilization of snail protein. Cancer Lett. 2018;419:75–83.
Cuevas IC, Sahoo SS, Kumar A, Zhang H, Westcott J, Aguilar M, et al. Fbxw7 is a driver of uterine carcinosarcoma by promoting epithelial-mesenchymal transition. Proc Natl Acad Sci U S A. 2019;116(51):25880–90.
Qiao X, Lin J, Shen J, Chen Y, Zheng L, Ren H, et al. FBXO28 suppresses liver cancer invasion and metastasis by promoting PKA-dependent SNAI2 degradation. Oncogene. 2023;42(39):2878–91.
Kim HY, Kim YM, Hong S. DNAJB9 suppresses the metastasis of triple-negative breast cancer by promoting FBXO45-mediated degradation of ZEB1. Cell Death Dis. 2021;12(5):461.
Cui YH, Kang JH, Suh Y, Zhao Y, Yi JM, Bae IH, et al. Loss of FBXL14 promotes mesenchymal shift and radioresistance of non-small cell lung cancer by TWIST1 stabilization. Signal Transduct Target Ther. 2021;6(1):272.
Mo Y, Wang Y, Wang Y, Deng X, Yan Q, Fan C, et al. Circular RNA circPVT1 promotes nasopharyngeal carcinoma metastasis via the beta-TrCP/c-Myc/SRSF1 positive feedback loop. Mol Cancer. 2022;21(1):192.
Podmirseg SR, Jakel H, Ranches GD, Kullmann MK, Sohm B, Villunger A, et al. Caspases uncouple p27(Kip1) from cell cycle regulated degradation and abolish its ability to stimulate cell migration and invasion. Oncogene. 2016;35(35):4580–90.
Sahu SK, Tiwari N, Pataskar A, Zhuang Y, Borisova M, Diken M, et al. FBXO32 promotes microenvironment underlying epithelial-mesenchymal transition via CtBP1 during tumour metastasis and brain development. Nat Commun. 2017;8(1):1523.
Bagger SO, Hopkinson BM, Pandey DP, Bak M, Brydholm AV, Villadsen R, et al. Aggressiveness of non-EMT breast cancer cells relies on FBXO11 activity. Mol Cancer. 2018;17(1):171.
Zhao Y, Shim N, Cui YH, Kang JH, Yoo KC, Kim S, et al. FBXO15 plays a critical suppressive functional role in regulation of breast cancer progression. Signal Transduct Target Ther. 2021;6(1):211.
Cao J, Zhao M, Liu J, Zhang X, Pei Y, Wang J, et al. RACK1 promotes Self-Renewal and chemoresistance of cancer stem cells in human hepatocellular carcinoma through stabilizing Nanog. Theranostics. 2019;9(3):811–28.
Xiao G, Lu W, Yuan J, Liu Z, Wang P, Fan H. Fbxw7 suppresses carcinogenesis and stemness in triple-negative breast cancer through CHD4 degradation and Wnt/beta-catenin pathway Inhibition. J Transl Med. 2024;22(1):99.
Yin Y, Xie CM, Li H, Tan M, Chen G, Schiff R, et al. The FBXW2-MSX2-SOX2 axis regulates stem cell property and drug resistance of cancer cells. Proc Natl Acad Sci U S A. 2019;116(41):20528–38.
Zhao X, Shu D, Sun W, Si S, Ran W, Guo B, et al. PLEK2 promotes cancer stemness and tumorigenesis of head and neck squamous cell carcinoma via the c-Myc-mediated positive feedback loop. Cancer Commun (Lond). 2022;42(10):987–1007.
Yao J, Wang XP, Yang J, Yang Z, Zhang ZY. SCF-FBXL8 contributes to liver metastasis and stem-cell-like features in colorectal cancer cells by mediating ubiquitination and degradation of TP53. Clin Transl Med. 2023;13(3):e1208.
Zhu X, Wang F, Wu X, Li Z, Wang Z, Ren X, et al. FBX8 promotes metastatic dormancy of colorectal cancer in liver. Cell Death Dis. 2020;11(8):622.
Fontana R, Mestre-Farrera A, Yang J. Update on Epithelial-Mesenchymal plasticity in cancer progression. Annu Rev Pathol. 2024;19:133–56.
Banito A, Li X, Laporte AN, Roe JS, Sanchez-Vega F, Huang CH, et al. The SS18-SSX oncoprotein hijacks KDM2B-PRC1.1 to drive synovial sarcoma. Cancer Cell. 2018;33(3):527–41. e8.
Li S, Chen Y, Xie Y, Zhan H, Zeng Y, Zeng K, et al. FBXO7 confers mesenchymal properties and chemoresistance in glioblastoma by controlling Rbfox2-Mediated alternative splicing. Adv Sci (Weinh). 2023;10(33):e2303561.
Debnath J, Gammoh N, Ryan KM. Autophagy and autophagy-related pathways in cancer. Nat Rev Mol Cell Biol. 2023;24(8):560–75.
Zhao Y, Xiong X, Sun Y. DEPTOR, an mTOR inhibitor, is a physiological substrate of SCF(betaTrCP) E3 ubiquitin ligase and regulates survival and autophagy. Mol Cell. 2011;44(2):304–16.
Xie CM, Tan M, Lin XT, Wu D, Jiang Y, Tan Y, et al. The FBXW7-SHOC2-Raptor axis controls the Cross-Talks between the RAS-ERK and mTORC1 signaling pathways. Cell Rep. 2019;26(11):3037–50. e4.
Suzuki N, Johmura Y, Wang TW, Migita T, Wu W, Noguchi R, et al. TP53/p53-FBXO22-TFEB controls basal autophagy to govern hormesis. Autophagy. 2021;17(11):3776–93.
Zhang Z, Liu X, Chu C, Zhang Y, Li W, Yu X, et al. MIR937 amplification potentiates ovarian cancer progression by attenuating FBXO16 Inhibition on ULK1-mediated autophagy. Cell Death Dis. 2024;15(10):735.
Song W, Zeng Z, Zhang Y, Li H, Cheng H, Wang J, et al. CircRNF144B/miR-342-3p/FBXL11 axis reduced autophagy and promoted the progression of ovarian cancer by increasing the ubiquitination of Beclin-1. Cell Death Dis. 2022;13(10):857.
Vargas JNS, Hamasaki M, Kawabata T, Youle RJ, Yoshimori T. The mechanisms and roles of selective autophagy in mammals. Nat Rev Mol Cell Biol. 2023;24(3):167–85.
Deng R, Zhang HL, Huang JH, Cai RZ, Wang Y, Chen YH, et al. MAPK1/3 kinase-dependent ULK1 degradation attenuates mitophagy and promotes breast cancer bone metastasis. Autophagy. 2021;17(10):3011–29.
Nguyen-Dien GT, Townsend B, Kulkarni PG, Kozul KL, Ooi SS, Eldershaw DN, et al. PPTC7 antagonizes mitophagy by promoting BNIP3 and NIX degradation via SCF(FBXL4). EMBO Rep. 2024;25(8):3324–47.
Yoshida Y, Yasuda S, Fujita T, Hamasaki M, Murakami A, Kawawaki J, et al. Ubiquitination of exposed glycoproteins by SCF(FBXO27) directs damaged lysosomes for autophagy. Proc Natl Acad Sci U S A. 2017;114(32):8574–9.
Cui D, Dai X, Shu J, Ma Y, Wei D, Xiong X, et al. The cross talk of two family members of beta-TrCP in the regulation of cell autophagy and growth. Cell Death Differ. 2020;27(3):1119–33.
Chen X, Kang R, Kroemer G, Tang D. Broadening horizons: the role of ferroptosis in cancer. Nat Rev Clin Oncol. 2021;18(5):280–96.
Huang G, Xiang Z, Wu H, He Q, Dou R, Lin Z, et al. The LncRNA BDNF-AS/WDR5/FBXW7 axis mediates ferroptosis in gastric cancer peritoneal metastasis by regulating VDAC3 ubiquitination. Int J Biol Sci. 2022;18(4):1415–33.
Ye Z, Zhuo Q, Hu Q, Xu X, Mengqi L, Zhang Z, et al. FBW7-NRA41-SCD1 axis synchronously regulates apoptosis and ferroptosis in pancreatic cancer cells. Redox Biol. 2021;38:101807.
Chen TC, Chuang JY, Ko CY, Kao TJ, Yang PY, Yu CH, et al. AR ubiquitination induced by the Curcumin analog suppresses growth of temozolomide-resistant glioblastoma through disrupting GPX4-Mediated redox homeostasis. Redox Biol. 2020;30:101413.
Zhu Z, Zheng Y, He H, Yang L, Yang J, Li M, et al. FBXO31 sensitizes cancer stem cells-like cells to cisplatin by promoting ferroptosis and facilitating proteasomal degradation of GPX4 in cholangiocarcinoma. Liver Int. 2022;42(12):2871–88.
Zhou P, Peng X, Zhang K, Cheng J, Tang M, Shen L, et al. HAT1/HDAC2 mediated ACSL4 acetylation confers radiosensitivity by inducing ferroptosis in nasopharyngeal carcinoma. Cell Death Dis. 2025;16(1):160.
Zhou Q, Meng Y, Li D, Yao L, Le J, Liu Y, et al. Ferroptosis in cancer: from molecular mechanisms to therapeutic strategies. Signal Transduct Target Ther. 2024;9(1):55.
Lei G, Zhuang L, Gan B. The roles of ferroptosis in cancer: tumor suppression, tumor microenvironment, and therapeutic interventions. Cancer Cell. 2024;42(4):513–34.
Denton D, Kumar S. Autophagy-dependent cell death. Cell Death Differ. 2019;26(4):605–16.
Liang Y, Chen P, Wang S, Cai L, Zhu F, Jiang Y, et al. SCF(FBXW5)-mediated degradation of AQP3 suppresses autophagic cell death through the PDPK1-AKT-MTOR axis in hepatocellular carcinoma cells. Autophagy. 2024;20(9):1984–99.
Agrawal Y, Sharma T, Islam S, Nadkarni KS, Santra MK. F-box protein FBXO41 suppresses breast cancer growth by inducing autophagic cell death through facilitating proteasomal degradation of oncogene SKP2. Int J Biochem Cell Biol. 2022;147:106228.
Li M, Lu H, Ruan C, Ke Q, Hu L, Li Z, et al. CircMAPK1 induces cell pyroptosis in sepsis-induced lung injury by mediating KDM2B mRNA decay to epigenetically regulate WNK1. Mol Med. 2024;30(1):155.
Wang Q, Huang PY, Wu JG, Zhang TQ, Li LF, Huang LD, et al. miR-219a-5p inhibits the pyroptosis in knee osteoarthritis by inactivating the NLRP3 signaling via targeting FBXO3. Environ Toxicol. 2022;37(11):2673–82.
Faubert B, Solmonson A, DeBerardinis RJ. Metabolic reprogramming and cancer progression. Science. 2020;368(6487):eaaw5473.
Hu T, Liu H, Liang Z, Wang F, Zhou C, Zheng X, et al. Tumor-intrinsic CD47 signal regulates Glycolysis and promotes colorectal cancer cell growth and metastasis. Theranostics. 2020;10(9):4056–72.
Zhang P, Shao Y, Quan F, Liu L, Yang J. FBP1 enhances the radiosensitivity by suppressing Glycolysis via the FBXW7/mTOR axis in nasopharyngeal carcinoma cells. Life Sci. 2021;283:119840.
Ji S, Qin Y, Liang C, Huang R, Shi S, Liu J, et al. FBW7 (F-box and WD repeat Domain-Containing 7) negatively regulates glucose metabolism by targeting the c-Myc/TXNIP (Thioredoxin-Binding Protein) axis in pancreatic cancer. Clin Cancer Res. 2016;22(15):3950–60.
Guo X, Zhu Y, Hong X, Zhang M, Qiu X, Wang Z, et al. miR-181d and c-myc-mediated Inhibition of CRY2 and FBXL3 reprograms metabolism in colorectal cancer. Cell Death Dis. 2017;8(7):e2958.
Chan CH, Li CF, Yang WL, Gao Y, Lee SW, Feng Z, et al. The Skp2-SCF E3 ligase regulates Akt ubiquitination, glycolysis, Herceptin sensitivity, and tumorigenesis. Cell. 2012;149(5):1098–111.
Rong Z, Yang J, Liu J, Meng Q, Hua J, Tan Z, et al. Dense stroma activates the TGF-beta1/FBW7 axis to induce metabolic subtype switching in pancreatic cancer. Int J Surg. 2025;111(2):1891–903.
Wei W, Qin B, Wen W, Zhang B, Luo H, Wang Y, et al. FBXW7beta loss-of-function enhances FASN-mediated lipogenesis and promotes colorectal cancer growth. Signal Transduct Target Ther. 2023;8(1):187.
Zhang H, Xia P, Yang Z, Liu J, Zhu Y, Huang Z, et al. Cullin-associated and neddylation-dissociated 1 regulate reprogramming of lipid metabolism through SKP1-Cullin-1-F-box(FBXO11) -mediated heterogeneous nuclear ribonucleoprotein A2/B1 ubiquitination and promote hepatocellular carcinoma. Clin Transl Med. 2023;13(10):e1443.
Luo L, Wu X, Fan J, Dong L, Wang M, Zeng Y, et al. FBXO7 ubiquitinates PRMT1 to suppress Serine synthesis and tumor growth in hepatocellular carcinoma. Nat Commun. 2024;15(1):4790.
Chavdoula E, Anastas V, La Ferlita A, Aldana J, Carota G, Spampinato M, et al. Transcriptional regulation of amino acid metabolism by KDM2B, in the context of ncPRC1.1 and in concert with MYC and ATF4. Metabolism. 2024;150:155719.
Ferrer CM, Lynch TP, Sodi VL, Falcone JN, Schwab LP, Peacock DL, et al. O-GlcNAcylation regulates cancer metabolism and survival stress signaling via regulation of the HIF-1 pathway. Mol Cell. 2014;54(5):820–31.
Zhang N, Meng Y, Mao S, Ni H, Huang C, Shen L, et al. FBXO31-mediated ubiquitination of OGT maintains O-GlcNAcylation homeostasis to restrain endometrial malignancy. Nat Commun. 2025;16(1):1274.
Hayes JD, Dinkova-Kostova AT, Tew KD. Oxidative stress in cancer. Cancer Cell. 2020;38(2):167–97.
Wang JY, Liu GZ, Wilmott JS, La T, Feng YC, Yari H, et al. Skp2-Mediated stabilization of MTH1 promotes survival of melanoma cells upon oxidative stress. Cancer Res. 2017;77(22):6226–39.
Ji J, Jing A, Ding Y, Ma X, Qian Q, Geng T, et al. FBXO5-mediated RNF183 degradation prevents Endoplasmic reticulum stress-induced apoptosis and promotes colon cancer progression. Cell Death Dis. 2024;15(1):33.
Li J, Zhao L, Wu Z, Huang S, Wang J, Chang Y, et al. SelK promotes glioblastoma cell proliferation by inhibiting beta-TrCP1 mediated ubiquitin-dependent degradation of CDK4. J Exp Clin Cancer Res. 2024;43(1):231.
Mori A, Masuda K, Ohtsuka H, Shijo M, Ariake K, Fukase K, et al. FBXW7 modulates malignant potential and cisplatin-induced apoptosis in cholangiocarcinoma through NOTCH1 and MCL1. Cancer Sci. 2018;109(12):3883–95.
Li N, Babaei-Jadidi R, Lorenzi F, Spencer-Dene B, Clarke P, Domingo E, et al. An FBXW7-ZEB2 axis links EMT and tumour microenvironment to promote colorectal cancer stem cells and chemoresistance. Oncogenesis. 2019;8(3):13.
Liu J, Wei L, Miao Q, Zhan S, Chen P, Liu W, et al. MDM2 drives resistance to osimertinib by contextually disrupting FBW7-mediated destruction of MCL-1 protein in EGFR mutant NSCLC. J Exp Clin Cancer Res. 2024;43(1):302.
Xiao Y, Yin C, Wang Y, Lv H, Wang W, Huang Y, et al. FBXW7 deletion contributes to lung tumor development and confers resistance to gefitinib therapy. Mol Oncol. 2018;12(6):883–95.
Wu X, Iwatsuki M, Takaki M, Saito T, Hayashi T, Kondo M, et al. FBXW7 regulates the sensitivity of Imatinib in Gastrointestinal stromal tumors by targeting MCL1. Gastric Cancer. 2024;27(2):235–47.
Richter KT, Kschonsak YT, Vodicska B, Hoffmann I. FBXO45-MYCBP2 regulates mitotic cell fate by targeting FBXW7 for degradation. Cell Death Differ. 2020;27(2):758–72.
Salaroglio IC, Belisario DC, Bironzo P, Ananthanarayanan P, Ricci L, Digiovanni S, et al. SKP2 drives the sensitivity to neddylation inhibitors and cisplatin in malignant pleural mesothelioma. J Exp Clin Cancer Res. 2022;41(1):75.
Lohmuller M, Roeck BF, Szabo TG, Schapfl MA, Pegka F, Herzog S, et al. The SKP2-p27 axis defines susceptibility to cell death upon CHK1 Inhibition. Mol Oncol. 2022;16(15):2771–87.
Ren C, Han X, Lu C, Yang T, Qiao P, Sun Y, et al. Ubiquitination of NF-kappaB p65 by FBXW2 suppresses breast cancer stemness, tumorigenesis, and Paclitaxel resistance. Cell Death Differ. 2022;29(2):381–92.
Zhu H, Wang X, Zhou X, Lu S, Gu G, Liu C. E3 ubiquitin ligase FBXW7 enhances radiosensitivity of non-small cell lung cancer cells by inhibiting SOX9 regulation of CDKN1A through ubiquitination. Lab Invest. 2022;102(11):1203–13.
Cui D, Xiong X, Shu J, Dai X, Sun Y, Zhao Y. FBXW7 confers radiation survival by targeting p53 for degradation. Cell Rep. 2020;30(2):497–509. e4.
Zhou Z, Zhang B, Deng Y, Deng S, Li J, Wei W, et al. FBW7/GSK3beta mediated degradation of IGF2BP2 inhibits IGF2BP2-SLC7A5 positive feedback loop and radioresistance in lung cancer. J Exp Clin Cancer Res. 2024;43(1):34.
Chen Y, Zhou Y, Feng X, Wu Z, Yang Y, Rao X, et al. Targeting FBXO22 enhances radiosensitivity in non-small cell lung cancer by inhibiting the FOXM1/Rad51 axis. Cell Death Dis. 2024;15(1):104.
Song Q, Wen J, Li W, Xue J, Zhang Y, Liu H, et al. HSP90 promotes radioresistance of cervical cancer cells via reducing FBXO6-mediated CD147 polyubiquitination. Cancer Sci. 2022;113(4):1463–74.
Gstalder C, Liu D, Miao D, Lutterbach B, DeVine AL, Lin C, et al. Inactivation of Fbxw7 impairs DsRNA sensing and confers resistance to PD-1 Blockade. Cancer Discov. 2020;10(9):1296–311.
Shen JZ, Qiu Z, Wu Q, Finlay D, Garcia G, Sun D, et al. FBXO44 promotes DNA replication-coupled repetitive element Silencing in cancer cells. Cell. 2021;184(2):352–69. e23.
Liu W, Ren D, Xiong W, Jin X, Zhu L. A novel FBW7/NFAT1 axis regulates cancer immunity in sunitinib-resistant renal cancer by inducing PD-L1 expression. J Exp Clin Cancer Res. 2022;41(1):38.
De S, Holvey-Bates EG, Mahen K, Willard B, Stark GR. The ubiquitin E3 ligase FBXO22 degrades PD-L1 and sensitizes cancer cells to DNA damage. Proc Natl Acad Sci U S A. 2021;118:47.
Zhang J, Lin XT, Yu HQ, Fang L, Wu D, Luo YD, et al. Elevated FBXL6 expression in hepatocytes activates VRK2-transketolase-ROS-mTOR-mediated immune evasion and liver cancer metastasis in mice. Exp Mol Med. 2023;55(10):2162–76.
Lin XT, Zhang J, Liu ZY, Wu D, Fang L, Li CM, et al. Elevated FBXW10 drives hepatocellular carcinoma tumorigenesis via AR-VRK2 phosphorylation-dependent GAPDH ubiquitination in male Transgenic mice. Cell Rep. 2023;42(7):112812.
Chan KL, Gomez J, Cardinez C, Kumari N, Sparbier CE, Lam EYN, et al. Inhibition of the CtBP complex and FBXO11 enhances MHC class II expression and anti-cancer immune responses. Cancer Cell. 2022;40(10):1190–206. e9.
Tian T, Xie X, Yi W, Zhou Y, Xu Y, Wang Z, et al. FBXO38 mediates FGL1 ubiquitination and degradation to enhance cancer immunity and suppress inflammation. Cell Rep. 2023;42(11):113362.
Meng X, Liu X, Guo X, Jiang S, Chen T, Hu Z, et al. FBXO38 mediates PD-1 ubiquitination and regulates anti-tumour immunity of T cells. Nature. 2018;564(7734):130–5.
Shi Y, Zheng X, Peng H, Xu C, Sun R, Tian Z, et al. The E3 ubiquitin ligase FBXO38 maintains the antitumor function of natural killer cells by sustaining IL15R signaling. Cancer Immunol Res. 2024;12(10):1438–51.
Harris R, Yang M, Schmidt C, Royet C, Singh S, Natarajan A et al. Fbxo7 promotes Cdk6 activity to inhibit PFKP and Glycolysis in T cells. J Cell Biol. 2022;221(7):e202203095.
Sun R, Lim SO. FBXL20-mediated ubiquitination triggers the proteasomal degradation of 4-1BB. FEBS J. 2022;289(15):4549–63.
Li G, Wen Z, Xiong S. Microenvironmental beta-TrCP negates amino acid transport to trigger CD8(+) T cell exhaustion in human non-small cell lung cancer. Cell Rep. 2025;44(1):115128.
Flugel D, Gorlach A, Kietzmann T. GSK-3beta regulates cell growth, migration, and angiogenesis via Fbw7 and USP28-dependent degradation of HIF-1alpha. Blood. 2012;119(5):1292–301.
Kim YJ, Zhao Y, Myung JK, Yi JM, Kim MJ, Lee SJ. Suppression of breast cancer progression by FBXL16 via oxygen-independent regulation of HIF1alpha stability. Cell Rep. 2021;37(8):109996.
Machado-Oliveira G, Guerreiro E, Matias AC, Facucho-Oliveira J, Pacheco-Leyva I, Braganca J. FBXL5 modulates HIF-1alpha transcriptional activity by degradation of CITED2. Arch Biochem Biophys. 2015;576:61–72.
Lei Z, Luo Y, Lu J, Fu Q, Wang C, Chen Q, et al. FBXO22 promotes HCC angiogenesis and metastasis via RPS5/AKT/HIF-1alpha/VEGF-A signaling axis. Cancer Gene Ther. 2025;32(2):198–213.
Zhang ZY, Sun JH, Liang MJ, Wang XP, Guan J, Zhou ZQ. The E3 ubiquitin ligase SCF (FBXW10)-mediated LATS2 degradation regulates angiogenesis and liver metastasis in colorectal cancer. Int J Biochem Cell Biol. 2023;158:106408.
Shaik S, Nucera C, Inuzuka H, Gao D, Garnaas M, Frechette G, et al. SCF(beta-TRCP) suppresses angiogenesis and thyroid cancer cell migration by promoting ubiquitination and destruction of VEGF receptor 2. J Exp Med. 2012;209(7):1289–307.
Dudley AC, Griffioen AW. Pathological angiogenesis: mechanisms and therapeutic strategies. Angiogenesis. 2023;26(3):313–47.
Yin L, Zhang J, Zhu Z, Peng X, Lan H, Ayoub A, et al. The FBXW7-KMT2 axis in cancer-associated fibroblasts controls tumor growth via an epigenetic-paracrine mechanism. Proc Natl Acad Sci U S A. 2025;122(13):e2423130122.
Chen JY, Li CF, Lai YS, Hung WC. Lysine demethylase 2A expression in cancer-associated fibroblasts promotes breast tumour growth. Br J Cancer. 2021;124(2):484–93.
Hu JL, Wang W, Lan XL, Zeng ZC, Liang YS, Yan YR, et al. CAFs secreted exosomes promote metastasis and chemotherapy resistance by enhancing cell stemness and epithelial-mesenchymal transition in colorectal cancer. Mol Cancer. 2019;18(1):91.
Yang N, Chen T, Wang L, Liu R, Niu Y, Sun L, et al. CXCR4 mediates matrix stiffness-induced downregulation of UBTD1 driving hepatocellular carcinoma progression via YAP signaling pathway. Theranostics. 2020;10(13):5790–801.
Enriqué Steinberg JH, Rossi FA, Magliozzi R, Yuniati L, Santucci M, Rossi M, et al. SCF(βTrCP)-mediated degradation of SHARP1 in triple-negative breast cancer. Cell Death Dis. 2023;14(11):726.
Li J, Zhao L, Wu Z, Huang S, Wang J, Chang Y, et al. SelK promotes glioblastoma cell proliferation by inhibiting β-TrCP1 mediated ubiquitin-dependent degradation of CDK4. J Experimental Clin Cancer Research: CR. 2024;43(1):231.
Barik GK, Sahay O, Mukhopadhyay A, Manne RK, Islam S, Roy A, et al. FBXW2 suppresses breast tumorigenesis by targeting AKT-Moesin-SKP2 axis. Cell Death Dis. 2023;14(9):623.
Yang F, Xu J, Li H, Tan M, Xiong X, Sun Y. FBXW2 suppresses migration and invasion of lung cancer cells via promoting β-catenin ubiquitylation and degradation. Nat Commun. 2019;10(1):1382.
Zhou T, Chen T, Lai B, Zhang W, Luo X, Xia D, et al. FBXW2 inhibits prostate cancer proliferation and metastasis via promoting EGFR ubiquitylation and degradation. Cell Mol Life Sci. 2022;79(5):268.
Xu F, Li J, Ni M, Cheng J, Zhao H, Wang S, et al. FBW7 suppresses ovarian cancer development by targeting the N(6)-methyladenosine binding protein YTHDF2. Mol Cancer. 2021;20(1):45.
Pan Y, Liu J, Gao Y, Guo Y, Wang C, Liang Z, et al. FBXW7 loss of function promotes esophageal squamous cell carcinoma progression via elevating MAP4 and ERK phosphorylation. J Exp Clin Cancer Res. 2023;42(1):75.
An HJ, Lee CJ, Lee GE, Choi Y, Jeung D, Chen W, et al. FBXW7-mediated ERK3 degradation regulates the proliferation of lung cancer cells. Exp Mol Med. 2022;54(1):35–46.
Liu Y, Wang Q, Guo Q, Zhu Y, Lin L, Yang C, et al. FBXW7 directly ubiquitinates and degrades CTNNB1 mediating the suppression of ENKUR in endometrial cancer. Int J Biol Sci. 2025;21(4):1801–18.
Lee CJ, An HJ, Kim SM, Yoo SM, Park J, Lee GE, et al. FBXW7-mediated stability regulation of signal transducer and activator of transcription 2 in melanoma formation. Proc Natl Acad Sci USA. 2020;117(1):584–94.
Kourtis N, Moubarak RS, Aranda-Orgilles B, Lui K, Aydin IT, Trimarchi T, et al. FBXW7 modulates cellular stress response and metastatic potential through HSF1 post-translational modification. Nat Cell Biol. 2015;17(3):322–32.
Huang LY, Zhao J, Chen H, Wan L, Inuzuka H, Guo J, et al. SCF(FBW7)-mediated degradation of Brg1 suppresses gastric cancer metastasis. Nat Commun. 2018;9(1):3569.
Kuai X, Li L, Chen R, Wang K, Chen M, Cui B, et al. SCF(FBXW7)/GSK3β-Mediated GFI1 degradation suppresses proliferation of gastric cancer cells. Cancer Res. 2019;79(17):4387–98.
Saffie R, Zhou N, Rolland D, Önder Ö, Basrur V, Campbell S, et al. FBXW7 triggers degradation of KMT2D to favor growth of diffuse large B-cell lymphoma cells. Cancer Res. 2020;80(12):2498–511.
Zhang E, Chen S, Tang H, Fei C, Yuan Z, Mu X, et al. CDK1/FBXW7 facilitates degradation and ubiquitination of MLST8 to inhibit progression of renal cell carcinoma. Cancer Sci. 2022;113(1):91–108.
Xiao G, Lu W, Yuan J, Liu Z, Wang P, Fan H. Fbxw7 suppresses carcinogenesis and stemness in triple-negative breast cancer through CHD4 degradation and Wnt/β-catenin pathway Inhibition. J Translational Med. 2024;22(1):99.
Li C, Deng C, Pan G, Wang X, Zhang K, Dong Z, et al. Lycorine hydrochloride inhibits cell proliferation and induces apoptosis through promoting FBXW7-MCL1 axis in gastric cancer. J Experimental Clin Cancer Research: CR. 2020;39(1):230.
Yao S, Xu F, Chen Y, Ge Y, Zhang F, Huang H, et al. Fbw7 regulates apoptosis in activated B-cell like diffuse large B-cell lymphoma by targeting Stat3 for ubiquitylation and degradation. J Experimental Clin Cancer Research: CR. 2017;36(1):10.
Liu ZY, Lin XT, Zhang YJ, Gu YP, Yu HQ, Fang L, et al. FBXW10-S6K1 promotes ANXA2 polyubiquitination and KRAS activation to drive hepatocellular carcinoma development in males. Cancer Lett. 2023;566:216257.
Yao J, Yang J, Yang Z, Wang XP, Yang T, Ji B, et al. FBXW11 contributes to stem-cell-like features and liver metastasis through regulating HIC1-mediated SIRT1 transcription in colorectal cancer. Cell Death Dis. 2021;12(10):930.
Roberts JZ, Holohan C, Sessler T, Fox J, Crawford N, Riley JS, et al. The SCF(Skp2) ubiquitin ligase complex modulates TRAIL-R2-induced apoptosis by regulating FLIP(L). Cell Death Differ. 2020;27(9):2726–41.
Wang J, Aldahamsheh O, Ferrena A, Borjihan H, Singla A, Yaguare S, et al. The interaction of SKP2 with p27 enhances the progression and stemness of osteosarcoma. Ann N Y Acad Sci. 2021;1490(1):90–104.
Kuchay S, Giorgi C, Simoneschi D, Pagan J, Missiroli S, Saraf A, et al. PTEN counteracts FBXL2 to promote IP3R3- and Ca(2+)-mediated apoptosis limiting tumour growth. Nature. 2017;546(7659):554–8.
Niu M, Xu J, Liu Y, Li Y, He T, Ding L, et al. FBXL2 counteracts Grp94 to destabilize EGFR and inhibit EGFR-driven NSCLC growth. Nat Commun. 2021;12(1):5919.
Yao H, Su S, Xia D, Wang M, Li Z, Chen W et al. F-box and leucine-rich repeat protein 5 promotes colon cancer progression by modulating PTEN/PI3K/AKT signaling pathway. Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie. 2018;107:1712-9.
Li Y, Cui K, Zhang Q, Li X, Lin X, Tang Y, et al. FBXL6 degrades phosphorylated p53 to promote tumor growth. Cell Death Differ. 2021;28(7):2112–25.
Shi W, Feng L, Dong S, Ning Z, Hua Y, Liu L, et al. FBXL6 governs c-MYC to promote hepatocellular carcinoma through ubiquitination and stabilization of HSP90AA1. Cell Commun Signal. 2020;18(1):100.
Xiong HJ, Yu HQ, Zhang J, Fang L, Wu D, Lin XT, et al. Elevated FBXL6 activates both wild-type KRAS and mutant KRAS(G12D) and drives HCC tumorigenesis via the ERK/mTOR/PRELID2/ROS axis in mice. Military Med Res. 2023;10(1):68.
Moro L, Simoneschi D, Kurz E, Arbini AA, Jang S, Guaragnella N, et al. Epigenetic Silencing of the ubiquitin ligase subunit FBXL7 impairs c-SRC degradation and promotes epithelial-to-mesenchymal transition and metastasis. Nat Cell Biol. 2020;22(9):1130–42.
Yoshida A, Choi J, Jin HR, Li Y, Bajpai S, Qie S, et al. Fbxl8 suppresses lymphoma growth and hematopoietic transformation through degradation of Cyclin D3. Oncogene. 2021;40(2):292–306.
Yang Y, Li S, Li B, Li Y, Xia K, Aman S, et al. FBXL10 promotes ERRα protein stability and proliferation of breast cancer cells by enhancing the mono-ubiquitylation of ERRα. Cancer Lett. 2021;502:108–19.
Cui YH, Kim H, Lee M, Yi JM, Kim RK, Uddin N, et al. FBXL14 abolishes breast cancer progression by targeting CDCP1 for proteasomal degradation. Oncogene. 2018;37(43):5794–809.
Fang X, Zhou W, Wu Q, Huang Z, Shi Y, Yang K, et al. Deubiquitinase USP13 maintains glioblastoma stem cells by antagonizing FBXL14-mediated Myc ubiquitination. J Exp Med. 2017;214(1):245–67.
Morel M, Long W. FBXL16 promotes cell growth and drug resistance in lung adenocarcinomas with KRAS mutation by stabilizing IRS1 and upregulating IRS1/AKT signaling. Mol Oncol. 2024;18(3):762–77.
Zhang J, Yang Z, Ou J, Xia X, Zhi F, Cui J. The F-box protein FBXL18 promotes glioma progression by promoting K63-linked ubiquitination of Akt. FEBS Lett. 2017;591(1):145–54.
Yu HQ, Li F, Xiong H, Fang L, Zhang J, Bie P et al. Elevated FBXL18 promotes RPS15A ubiquitination and SMAD3 activation to drive HCC. Hepatology communications. 2023;7(7):e00198.
Manne RK, Agrawal Y, Malonia SK, Banday S, Edachery S, Patel A, et al. FBXL20 promotes breast cancer malignancy by inhibiting apoptosis through degradation of PUMA and BAX. J Biol Chem. 2021;297(4):101253.
Lee GE, Jeung D, Chen W, Byun J, Lee JY, Kang HC, et al. MEKs/ERKs-mediated FBXO1/E2Fs interaction interference modulates G(1)/S cell cycle transition and cancer cell proliferation. Arch Pharm Res. 2023;46(1):44–58.
Ji J, Shen J, Xu Y, Xie M, Qian Q, Qiu T, et al. FBXO2 targets glycosylated SUN2 for ubiquitination and degradation to promote ovarian cancer development. Cell Death Dis. 2022;13(5):442.
Che X, Jian F, Wang Y, Zhang J, Shen J, Cheng Q, et al. FBXO2 promotes proliferation of endometrial cancer by Ubiquitin-Mediated degradation of FBN1 in the regulation of the cell cycle and the autophagy pathway. Front Cell Dev Biology. 2020;8:843.
Qie S, Majumder M, Mackiewicz K, Howley BV, Peterson YK, Howe PH, et al. Fbxo4-mediated degradation of Fxr1 suppresses tumorigenesis in head and neck squamous cell carcinoma. Nat Commun. 2017;8(1):1534.
Feng C, Yang F, Wang J. FBXO4 inhibits lung cancer cell survival by targeting Mcl-1 for degradation. Cancer Gene Ther. 2017;24(8):342–7.
Ji M, Zhao Z, Li Y, Xu P, Shi J, Li Z, et al. FBXO6-mediated RNASET2 ubiquitination and degradation governs the development of ovarian cancer. Cell Death Dis. 2021;12(4):317.
Zhang H, Zhao Y, Wang J, Li J, Xia J, Lin Y, et al. FBXO7, a tumor suppressor in endometrial carcinoma, suppresses INF2-associated mitochondrial division. Cell Death Dis. 2023;14(6):368.
FeiFei W, HongHai X, YongRong Y, PingXiang W, JianHua W, XiaoHui Z, et al. FBX8 degrades GSTP1 through ubiquitination to suppress colorectal cancer progression. Cell Death Dis. 2019;10(5):351.
Wang FF, Zhang XJ, Yan YR, Zhu XH, Yu J, Ding Y, et al. FBX8 is a metastasis suppressor downstream of miR-223 and targeting mTOR for degradation in colorectal carcinoma. Cancer Lett. 2017;388:85–95.
Xuan Z, Chen C, Sun H, Yang K, Li J, Fu M, et al. NDR1/FBXO11 promotes phosphorylation-mediated ubiquitination of β-catenin to suppress metastasis in prostate cancer. Int J Biol Sci. 2024;20(12):4957–77.
Pighi C, Cheong TC, Compagno M, Patrucco E, Arigoni M, Olivero M, et al. Frequent mutations of FBXO11 highlight BCL6 as a therapeutic target in Burkitt lymphoma. Blood Adv. 2021;5(23):5239–57.
Paul D, Islam S, Manne RK, Dinesh US, Malonia SK, Maity B, et al. F-box protein FBXO16 functions as a tumor suppressor by attenuating nuclear β-catenin function. J Pathol. 2019;248(3):266–79.
Ji M, Zhao Z, Li Y, Xu P, Shi J, Li Z, et al. FBXO16-mediated HnRNPL ubiquitination and degradation plays a tumor suppressor role in ovarian cancer. Cell Death Dis. 2021;12(8):758.
Dobish KK, Wittorf KJ, Swenson SA, Bean DC, Gavile CM, Woods NT, et al. FBXO21 mediated degradation of p85α regulates proliferation and survival of acute myeloid leukemia. Leukemia. 2023;37(11):2197–208.
Ge MK, Zhang N, Xia L, Zhang C, Dong SS, Li ZM, et al. FBXO22 degrades nuclear PTEN to promote tumorigenesis. Nat Commun. 2020;11(1):1720.
Zhu XN, He P, Zhang L, Yang S, Zhang HL, Zhu D, et al. FBXO22 mediates polyubiquitination and inactivation of LKB1 to promote lung cancer cell growth. Cell Death Dis. 2019;10(7):486.
Lignitto L, LeBoeuf SE, Homer H, Jiang S, Askenazi M, Karakousi TR, et al. Nrf2 activation promotes lung cancer metastasis by inhibiting the degradation of Bach1. Cell. 2019;178(2):316-329.e18.
Zhang H, Bai Y, Li J, Chen T, Shang G. FBXO22 promotes osteosarcoma progression via regulation of FOXO1 for ubiquitination and degradation. J Cell Mol Med. 2024;28(16):e70021.
Bai J, Wu K, Cao MH, Yang Y, Pan Y, Liu H, et al. SCF(FBXO22) targets HDM2 for degradation and modulates breast cancer cell invasion and metastasis. Proc Natl Acad Sci USA. 2019;116(24):11754–63.
Liu P, Cong X, Liao S, Jia X, Wang X, Dai W, et al. Global identification of phospho-dependent SCF substrates reveals a FBXO22 phosphodegron and an ERK-FBXO22-BAG3 axis in tumorigenesis. Cell Death Differ. 2022;29(1):1–13.
Zhu XN, Wei YS, Yang Q, Liu HR, Zhi Z, Zhu D, et al. FBXO22 promotes leukemogenesis by targeting BACH1 in MLL-rearranged acute myeloid leukemia. J Hematol Oncol. 2023;16(1):9.
Nie DY, Tabor JR, Li J, Kutera M, St-Germain J, Hanley RP, et al. Recruitment of FBXO22 for targeted degradation of NSD2. Nat Chem Biol. 2024;20(12):1597–607.
Lin M, Zhang J, Bouamar H, Wang Z, Sun LZ, Zhu X. Fbxo22 promotes cervical cancer progression via targeting p57(Kip2) for ubiquitination and degradation. Cell Death Dis. 2022;13(9):805.
Zhang L, Chen J, Ning D, Liu Q, Wang C, Zhang Z, et al. FBXO22 promotes the development of hepatocellular carcinoma by regulating the ubiquitination and degradation of p21. J Experimental Clin Cancer Research: CR. 2019;38(1):101.
Chen K, Wang Y, Dai X, Luo J, Hu S, Zhou Z, et al. FBXO31 is upregulated by METTL3 to promote pancreatic cancer progression via regulating SIRT2 ubiquitination and degradation. Cell Death Dis. 2024;15(1):37.
Duan S, Moro L, Qu R, Simoneschi D, Cho H, Jiang S, et al. Loss of FBXO31-mediated degradation of DUSP6 dysregulates ERK and PI3K-AKT signaling and promotes prostate tumorigenesis. Cell Rep. 2021;37(3):109870.
Su D, Wang R, Chen G, Ding C, Liu Y, Tao J, et al. FBXO32 stimulates protein synthesis to drive pancreatic cancer progression and metastasis. Cancer Res. 2024;84(16):2607–25.
Wu J, Wen T, Marzio A, Song D, Chen S, Yang C, et al. FBXO32-mediated degradation of PTEN promotes lung adenocarcinoma progression. Cell Death Dis. 2024;15(4):282.
Zhang N, Liao Y, Lv W, Zhu S, Qiu Y, Chen N, et al. FBXO32 targets PHPT1 for ubiquitination to regulate the growth of EGFR mutant lung cancer. Cell Oncol (Dordrecht Netherlands). 2022;45(2):293–307.
Zhou H, Liu Y, Zhu R, Ding F, Wan Y, Li Y, et al. FBXO32 suppresses breast cancer tumorigenesis through targeting KLF4 to proteasomal degradation. Oncogene. 2017;36(23):3312–21.
Wu Z, Peng Y, Chen W, Xia F, Song T, Ke Q. Lactylation-driven transcriptional activation of FBXO33 promotes gallbladder cancer metastasis by regulating p53 polyubiquitination. Cell Death Dis. 2025;16(1):144.
Zheng L, Shen J, Chen Y, Lin J, Li P, Zhao X, et al. FBXO43 promotes cell cycle progression in cancer cells through stabilizing SKP2. Cancer Lett. 2024;591:216848.
Lin XT, Yu HQ, Fang L, Tan Y, Liu ZY, Wu D et al. Elevated FBXO45 promotes liver tumorigenesis through enhancing IGF2BP1 ubiquitination and subsequent PLK1 upregulation. eLife. 2021;10:e70715.
Wang Q, Xu C, Cai R, An W, Yuan H, Xu M. Fbxo45-mediated NP-STEP(46) degradation via K6-linked ubiquitination sustains ERK activity in lung cancer. Mol Oncol. 2022;16(16):3017–33.
Zheng M, Wu L, Xiao R, Cai J, Chen W, Shen S. Fbxo45 facilitates the malignant progression of breast cancer by targeting Bim for ubiquitination and degradation. BMC Cancer. 2024;24(1):619.
Wu L, Yu K, Chen K, Zhu X, Yang Z, Wang Q, et al. Fbxo45 facilitates pancreatic carcinoma progression by targeting USP49 for ubiquitination and degradation. Cell Death Dis. 2022;13(3):231.
Xie W, Jiang Q, Wu X, Wang L, Gao B, Sun Z, et al. IKBKE phosphorylates and stabilizes snail to promote breast cancer invasion and metastasis. Cell Death Differ. 2022;29(8):1528–40.
Li F, Niu M, Qin K, Guo R, Yi Y, Xu J, et al. FBXL2 promotes E47 protein instability to inhibit breast cancer stemness and Paclitaxel resistance. Oncogene. 2023;42(5):339–50.
Yeh CH, Bellon M, Wang F, Zhang H, Fu L, Nicot C. Loss of FBXW7-mediated degradation of BRAF elicits resistance to BET inhibitors in adult T cell leukemia cells. Mol Cancer. 2020;19(1):139.
Patel A, Garcia LF, Mannella V, Gammon L, Borg TM, Maffucci T, et al. Targeting p63 upregulation abrogates resistance to MAPK inhibitors in melanoma. Cancer Res. 2020;80(12):2676–88.
Park S, Ryu WJ, Kim TY, Hwang Y, Han HJ, Lee JD, et al. Overcoming BRAF and CDK4/6 inhibitor resistance by inhibiting MAP3K3-dependent protection against YAP lysosomal degradation. Exp Mol Med. 2024;56(4):987–1000.
Zhou Z, Zhang B, Deng Y, Deng S, Li J, Wei W, et al. FBW7/GSK3β mediated degradation of IGF2BP2 inhibits IGF2BP2-SLC7A5 positive feedback loop and radioresistance in lung cancer. J Experimental Clin Cancer Research: CR. 2024;43(1):34.